Brought to you by 
Acucela helps develop Otsuka's rebamipide for dry eye
11 Sep 2008
Executive Summary
Acucela (oral small molecules for blinding diseases) and Otsuka Pharmaceutical have teamed up to co-develop the latter's Phase III rebamipide for dry eye, marking Otsuka's third ophthalmic-focused deal this year.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acucela helps develop Otsuka's rebamipide for dry eye
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice